HISTORY

~CURRENT
2022
  • Jan.

    Signed CDMO contract with BIOVIAN -
    Signed a MOU with MedySapiens

2021
  • Dec.

    Series A fundraising

  • Apr.

    ANL-105 domestic patent registration

  • Jan.

    ANL-104 domestic patent registratio

2020
  • Dec.

    Designated as a preclinical dementia study by a governmental agency of dementia R&D

  • Oct.

    Experimental medicine produced by OXGENE

  • Jul.

    ANL-101 patent registered in the US

  • Jun.

    ANL-104/105 transfer

2012~2019
2019
  • Dec.

    Corporate foundation

  • Jul.

    Angel capital raised

  • Jun.

    ANL-101 transfer completed

  • Apr.

    Established

2017
  • Dec.

    Animal model studies & patents

  • Sep.

    ANL-104 filed

  • Jul.

    ANL-101 registered in Korea
    ANL-105 filed

2015
  • Dec.

    ANL-101 (AD agent) patent filed

  • Jun.

    Filed in Republic of Korea
    Filed in US and CHINA (including PCT)

2012
  • Dec.

    Underlying technology - Mainly studied by Dr.Keetae Kim, the co-founder

  • Jan.

    Joint research by IBS(Institue for Basic Science, www.ibs.re.kr) and DGIST(www.dgist.ac.kr)
    Originally studied the relationship between aging and MicroRNA
    Found, in hippocampal neurons of mouse, aging-related miRNAs